Literature DB >> 3458231

Antagonism of phencyclidine action by metaphit in rat cerebellar Purkinje neurons: an electrophysiological study.

Y Wang, M Palmer, R Freedman, B Hoffer, M V Mattson, R A Lessor, K C Rice, A E Jacobson.   

Abstract

Metaphit (1-[1-(3-isothiocyanatophenyl)-cyclohexyl]piperidine), a derivative of the psychotomimetic drug phencyclidine (PCP), is postulated to bind irreversibly to PCP receptors. We examined here the electrophysiological interactions of metaphit with PCP in rat cerebellar cortex, since a specific effect of PCP on cerebellar neuronal circuitry has been shown. Metaphit, applied locally to Purkinje neurons by micropressure ejection through multibarreled micropipettes, has a reversible depressant action lasting for 5-20 min. Following this, PCP-induced inhibition is blocked with no recovery despite repeated applications of PCP for over an hour. This blockade was not seen unless the dose of metaphit was sufficient to transiently depress Purkinje neuron discharge. Metaphit does not antagonize inhibitory effects of locally applied norepinephrine or gamma-aminobutyric acid. This electrophysiological data suggests that metaphit is an irreversible antagonist of PCP in the cerebellum.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3458231      PMCID: PMC323372          DOI: 10.1073/pnas.83.8.2724

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Interrelationship between catecholamine-stimulated formation of adenosine 3',5'-monophosphate in cerebellar slices and inhibitory effects on cerebellar Purkinje cells: antagonism by neuroleptic compounds.

Authors:  P Skolnick; J W Daly; R Freedman; B J Hoffer
Journal:  J Pharmacol Exp Ther       Date:  1976-05       Impact factor: 4.030

2.  A quantitative microiontophoretic analysis of the responses of central neurones to noradrenaline: interactions with cobalt, manganese, verapamil and dichloroisoprenaline.

Authors:  R Freedman; B J Hoffer; D J Woodward
Journal:  Br J Pharmacol       Date:  1975-08       Impact factor: 8.739

3.  Neuronal actions of endorphins and enkephalins among brain regions: a comparative microiontophoretic study.

Authors:  R A Nicoll; G R Siggins; N Ling; F E Bloom; R Guillemin
Journal:  Proc Natl Acad Sci U S A       Date:  1977-06       Impact factor: 11.205

4.  A pressure system for intracellular and extracellular ejections of picoliter volumes.

Authors:  R E McCaman; D G McKenna; J K Ono
Journal:  Brain Res       Date:  1977-11-04       Impact factor: 3.252

5.  Interaction of phencyclidines with the muscarinic and opiate receptors in the central nervous system.

Authors:  J P Vincent; D Cavey; J M Kamenka; P Geneste; M Lazdunski
Journal:  Brain Res       Date:  1978-08-18       Impact factor: 3.252

6.  A specific acylating agent for the [3H]phencyclidine receptors in rat brain.

Authors:  M F Rafferty; M Mattson; A E Jacobson; K C Rice
Journal:  FEBS Lett       Date:  1985-02-25       Impact factor: 4.124

7.  Presynaptic dopaminergic activity of phencyclidine in rat caudate.

Authors:  S W Johnson; P E Haroldsen; B J Hoffer; R Freedman
Journal:  J Pharmacol Exp Ther       Date:  1984-04       Impact factor: 4.030

8.  Phencyclidine receptors in rat brain cortex.

Authors:  L G Mendelsohn; G A Kerchner; V Kalra; D M Zimmerman; J D Leander
Journal:  Biochem Pharmacol       Date:  1984-11-15       Impact factor: 5.858

9.  Effects of phencyclidine and its derivatives on enteric neurones.

Authors:  A R Gintzler; R S Zukin; S R Zukin
Journal:  Br J Pharmacol       Date:  1982-02       Impact factor: 8.739

Review 10.  NEUROBIOLOGY OF PHENCYCLIDINE (SERNYL), A DRUG WITH AN UNUSUAL SPECTRUM OF PHARMACOLOGICAL ACTIVITY.

Authors:  E F DOMINO
Journal:  Int Rev Neurobiol       Date:  1964       Impact factor: 3.230

View more
  1 in total

1.  Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors.

Authors:  K A Jacobson; S Barone; U Kammula; G L Stiles
Journal:  J Med Chem       Date:  1989-05       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.